BLAINJECTIONINJECTABLEPriority Review
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
9
Mechanism of Action
Amyloid Beta-directed Antibody Interactions
Pharmacologic Class:
Amyloid Beta-directed Antibody
Clinical Trials (5)
The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.
Started Dec 2025
60 enrolled
Alzheimers Disease
A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease
Started Feb 2025
3,000 enrolled
Alzheimer's Disease
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Started Sep 2024
105 enrolled
Alzheimer's Disease
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
Started Feb 2024
5,000 enrolled
Alzheimer's Disease
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
Started Sep 2022
160 enrolled
Healthy Volunteers